Quantcast

Latest Humanized antibody Stories

2010-05-04 07:30:00

INCLINE VILLAGE, Nev., May 4 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the Ninth Annual JMP Securities Research Conference in San Francisco on Wednesday, May 12, 2010 at 9:00 a.m. Pacific Time. To access the live and subsequently archived webcast of the conference call, go to the Company's website at http://www.pdl.com and go to "Company Presentations...

2010-03-24 04:30:00

NEW YORK, March 24 /PRNewswire-FirstCall/ -- Intellect Neurosciences, Inc. (OTC Bulletin Board: ILNS), a biopharmaceutical company focused on development of disease-modifying therapeutic agents for Alzheimer's disease ("AD"), announced today that its Chairman & Chief Executive Officer, Daniel Chain, PhD, will deliver the key note speech at a session entitled "Alzheimer's Monoclonal Antibodies" at the BIT Life Sciences 2nd International Conference on Monoclonal Antibodies. The...

2010-03-18 13:49:06

EUREKA project E! 3424 RECAN has developed a range of unique and highly specific monoclonal and polyclonal antibodies "“ the proteins produced in the blood which counteract bacteria, viruses or cancerous cells. This was achieved by first producing a number of recombinant proteins which are important components of cellular signaling pathways. These proteins themselves have direct uses in immunization and experimental studies. A further key advance is the incorporation of novel...

2010-03-16 07:30:00

INCLINE VILLAGE, Nev., March 16 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that the company will hold its annual meeting of stockholders on Wednesday, June 9, 2010 at 9:00a.m. Pacific Time for all stockholders of record on April 15, 2010. The meeting will take place at the Hyatt Regency Hotel in Incline Village, Nevada. About PDL BioPharma PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new...

2010-03-03 07:30:00

INCLINE VILLAGE, Nev., March 3 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the Cowen and Company 30th Annual Health Care Conference in Boston on Tuesday, March 9, 2010 at 1:30 p.m. Eastern Time. To access the live and subsequently archived webcast of the conference call, go to the company's website at http://www.pdl.com and go to "Company Presentations &...

1af4d21a83ad4e040d5c0acf30f15bd21
2010-02-23 10:30:04

How do you study-and try to cure in the laboratory-an infection that only humans can get? A team led by Salk Institute researchers does it by generating a mouse with an almost completely human liver. This "humanized" mouse is susceptible to human liver infections and responds to human drug treatments, providing a new way to test novel therapies for debilitating human liver diseases and other diseases with liver involvement such as malaria. "We found that, not only can we infect our humanized...

2010-02-03 18:01:00

LONDON, February 4 /PRNewswire/ -- A major centre created by the Medical Research Council (MRC) and MRC Technology (MRCT) in order to fast-track the discovery and development of novel drugs, opens its first call for targets today. The MRCT Centre for Therapeutics Discovery (CTD), based in London, is seeking small molecule drug discovery and therapeutic antibody targets from academic researchers. The CTD would like to collaborate with scientists in all universities to develop...

2010-02-02 07:00:00

INCLINE VILLAGE, Nev., Feb. 2 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the 12th Annual BIO CEO & Investor Conference in New York City on Monday, February 8, 2010 at 2:00 p.m. Eastern Time. To access the live and subsequently archived webcast of the conference call, go to the company's website at http://www.pdl.com and click "Investors." Please connect...

2010-01-12 03:00:00

LONDON and GOTTINGEN, Germany, January 12 /PRNewswire/ -- Reference MRCT: MRCT120110 Georg-August-University Gottingen, University of Regensburg and MRC Technology (MRCT) have signed exclusive license agreements through MBM ScienceBridge GmbH and in agreement with Bayerische Patentallianz GmbH, for the development of a novel therapy of inflammatory and immune diseases based on the depletion of inflammatory monocytes. The first targets will be rheumatoid arthritis (RA) and...

2010-01-11 06:30:00

Collaboration utilizes antibodies selectively targeting cancer cells combined with nuclear delivery technology developed at University of Toronto MISSISSAUGA, ON, Jan. 11 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM) today announced results of a collaboration with researchers at the University of Toronto for the development of highly potent antibody-radionuclide conjugates for use in the treatment of cancer. The approach has successfully concluded its first series of...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'